Hepatitis B market on hot competition

30-odd Korean companies are going to launch a generic version of Hepsera (adefovir dipivoxil) in July, thus shedding a red light on its competitive market.

Dosed as one oral 10 mg tablet, once daily, adefovir dipivoxil belongs to a novel class of drugs called nucleotide analogues, which are designed to work by blocking HBV DNA polymerase, an enzyme involved in the replication of HBV in the b...